At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 211 enrolled
Drug / intervention
pemetrexed +1 moredrug
Likely dose
pemetrexed 500 mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 3 Study of Pemetrexed Versus Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Had Prior Chemotherapy
In Brief
A Phase 3 clinical trial evaluating pemetrexed and docetaxel for Non-Small Cell Lung Cancer. Completed, enrolled 211 participants across 7 sites.
Detailed Summary
The purpose of this study is to compare the efficacy and toxicity of pemetrexed and docetaxel administered on a 3-weekly schedule in the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have had prior chemotherapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-Small Cell Lung Cancer
CountriesChina
Collaborators--
Timeline
Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartOct 2006
First PostedOct 2006
Primary CompletionDec 2008
Study CompletionJun 2010
TodayJul 2026
First PostedOct 23, 2006
Enrollment StartOct 1, 2006
Primary CompletionDec 1, 2008
Study CompletionJun 1, 2010
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 19.7 years ago
Interventions
pemetrexeddrug
500 mg/m2, intravenous (IV) every 21 days until disease progression, death or 12 months after enrollment
docetaxeldrug
75 mg/m2, intravenous (IV), every 21 days until disease progression, death or 12 months after enrollment